目的 观察通心络胶囊联合福辛普利治疗缺血性心肌病的临床疗效。方法 选取2015年1月—2017年1月在青岛思达心脏医院就诊的缺血性心肌病患者82例，随机分为对照组和治疗组，每组各41例。对照组口服福辛普利钠片，10 mg/次，1次/d；治疗组在对照组的基础上口服通心络胶囊，2～4粒/次，3次/d。两组患者均治疗2周。观察两组患者临床疗效和心电图疗效，同时比较治疗前后两组患者静息心率、收缩压、舒张压、三酰甘油（TG）、总胆固醇（CHO）、低密度脂蛋白（LDL-C）、N末端B型钠尿肽原（NT-proBNP）、左心室舒张末期内径（LVEDD）、左心室收缩末期内径（LVESD）和左室射血分数（LVEF）。结果 治疗后，对照组临床有效率和心电图疗效分别为73.17%和68.29%，均分别显著低于治疗组90.24%和87.80%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者静息心率、收缩压和舒张压均显著降低（P<0.05），且治疗组静息心率、收缩压和舒张压水平明显低于对照组（P<0.05）。治疗后，两组TG、CHO、LDL-C和NT-proBNP水平均显著降低（P<0.05），且治疗组TG、CHO、LDL-C和NT-proBNP水平明显低于对照组（P<0.05）。治疗后，两组LVEDD和LVESD显著降低（P<0.05），LVEF显著升高（P<0.05），且治疗组患者心功能明显好于对照组（P<0.05）。结论 通心络胶囊联合福辛普利治疗缺血性心肌病，能有效改善患者的临床症状、炎性反应和血脂水平。

Objective To observe the clinical effect of Tongxinluo Capsules combined with fosinopril in treatment of ischemic cardiomyopathy. Methods Patients (82 cases) with ischemic cardiomyopathy in Qingdao Starr Heart Hospital from January 2015 to January 2017 were randomly divided into control and treatment groups, and each group had 41 cases. Patients in the control group were po administered with Fosinopril Sodium Tablets, 10 mg/time, once daily. Patients in the treatment group were po administered with Tongxinluo Capsules on the basis of the control group, 2 - 4 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical and electrocardiogram efficacy were evaluated, and the resting heart rate, systolic and diastolic blood pressure, TG, CHO, LDL-C, NT-proBNP, LVEDD, LVESD and LVEF in two groups before and after treatment were compared. Results After treatment, the clinical and electrocardiogram efficacy in the control group were 73.17% and 68.29%, which were significantly lower than 90.24% and 87.80% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the resting heart rate, systolic and diastolic blood pressure in two groups were significantly decreased (P<0.05), which in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the ITG, CHO, LDL-C and NT-proBNP levels in two groups were significantly decreased (P<0.05), and these indicators in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the LVEDD and LVESD in two groups were significantly decreased (P<0.05), but LVEF was significantly increased (P<0.05), and the cardiac function indexes in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Tongxinluo Capsules combined with fosinopril in treatment of ischemic cardiomyopathy can effectively improve the clinical symptoms, the inflammatory response and blood lipid levels.